Carestream’s OnSight 3D Extremity System Receives FDA 510(k) Clearance

ROCHESTER, N.Y., Sept. 8 — The CARESTREAM OnSight 3D Extremity System that uses cone beam CT (CBCT) technology to capture weight-bearing and other types of extremity exams has received FDA 510(k) clearance and is available for order in the United States. This affordable, compact system offers high-quality, lower-dose 3D imaging studies for use by orthopaedic and sports medicine practices, hospitals, imaging centers, urgent care facilities and other healthcare providers. “Our extremity imaging system can help in treating a host of orthopaedic conditions that affect the biomechanical behavior of the joints such as arthritis, meniscus loss, instability and malalignment syndromes,” said Helen Titus, Carestream’s Worldwide Marketing Director for Ultrasound & CT Solutions. “This new system offers less radiation than traditional CT systems while delivering excellent image quality.” Orthopaedic imaging is a major focus for Carestream because of the prevalence of musculoskeletal conditions among people of all ages. “Youth and adults often suffer sports-related injuries to their knees, ankles and feet while older adults experience arthritis, joint instability, meniscus loss and other conditions,” Titus explains. Carestream’s new extremity imaging system enables healthcare providers to capture high-quality 3D images and conduct a patient consultation in a single visit—which helps improve productivity and convenience for both specialists and patients. An additional benefit is the ability for patients to view a 3D image that illustrates their condition or injury to help them understand the reason for a treatment or surgical procedure.   This new imaging system will be demonstrated at the American Society for Surgery of the Hand (ASSH) conference that begins on Sept. 29. Click here for an image of the CBCT system.

Around the web

The nuclear imaging isotope shortage of molybdenum-99 may be over now that the sidelined reactor is restarting. ASNC's president says PET and new SPECT technologies helped cardiac imaging labs better weather the storm.

CMS has more than doubled the CCTA payment rate from $175 to $357.13. The move, expected to have a significant impact on the utilization of cardiac CT, received immediate praise from imaging specialists.

The newly cleared offering, AutoChamber, was designed with opportunistic screening in mind. It can evaluate many different kinds of CT images, including those originally gathered to screen patients for lung cancer. 

Trimed Popup
Trimed Popup